NCT01732198View on ClinicalTrials.gov

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

PHASE2UnknownINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Infectious Disease
Interventions
BIOLOGICAL

NU300

BIOLOGICAL

ActHIB

BIOLOGICAL

Prevnar 13

Trial Locations (2)

40004

Bardstown

94611

Oakland

Sponsors

Lead Sponsor

Nuron Biotech Inc.
All Listed Sponsors
lead

Nuron Biotech Inc.

INDUSTRY